Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase
Research output: Contribution to journal › Journal article › Research › peer-review
Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) are promising cancer drugs currently in clinical trials in oncology, including APO866, CHS-828 and the CHS-828 prodrug EB1627/GMX1777, but cancer cell resistance to these drugs has not been studied in detail.
| Original language | English |
|---|---|
| Journal | BMC Cancer |
| Volume | 10 |
| Pages (from-to) | 677 |
| Number of pages | 13 |
| ISSN | 1471-2407 |
| DOIs | |
| Publication status | Published - 10 Dec 2010 |
- Faculty of Health and Medical Sciences
Research areas
ID: 32331205